Background
==========

Cardiovascular disease is the leading cause of mortality and a primary contributor to the burden of disease worldwide ([@b62-ehp0115-000472]). Environmental toxicants, including lead and other metals, are potentially preventable exposures that may explain population variation in cardiovascular disease rates ([@b9-ehp0115-000472]; [@b118-ehp0115-000472]). However, after more than 100 years since initial reports suggested a link between lead exposure and cardiovascular outcomes ([@b58-ehp0115-000472]; [@b63-ehp0115-000472]), the contribution of lead to cardiovascular disease is still incompletely understood.

Population research on the cardiovascular effects of lead has focused largely on the association with blood pressure and hypertension. Several reviews and metaanalyses combining data from more than 30 original studies and around 60,000 participants have examined the evidence relating blood lead to blood pressure or hypertension \[[@b41-ehp0115-000472]; [@b80-ehp0115-000472]; [@b96-ehp0115-000472]; [@b97-ehp0115-000472]; [@b103-ehp0115-000472], 1995; [@b115-ehp0115-000472]\]. All these reviews concluded that there was a positive association between blood lead levels and blood pressure ([Table 1](#t1-ehp0115-000472){ref-type="table"}). The estimated increase in systolic blood pressure associated with a 2-fold increase in blood lead levels (e.g., from 5 to 10 μg/dL) ranged across reviews from 0.6 to 1.25 mmHg. This epidemiologic relationship is also supported by a large body of experimental and mechanistic evidence ([@b115-ehp0115-000472]). Because lead exposure is widespread, even a modest effect would imply that lead exposure is an important determinant of blood pressure levels and hypertension in human populations.

The cardiovascular effects of lead, however, are not limited to increased blood pressure and hypertension. Lead exposure has also been associated with an increased incidence of clinical cardiovascular end points such as coronary heart disease, stroke, and peripheral arterial disease ([@b65-ehp0115-000472]; [@b71-ehp0115-000472]; [@b79-ehp0115-000472]; [@b91-ehp0115-000472]), and with other cardiovascular function abnormalities such as left ventricular hypertrophy and alterations in cardiac rhythm ([@b15-ehp0115-000472]; [@b95-ehp0115-000472]).

In the present article, our objective was to perform a systematic review of the epidemiologic evidence on the association of lead exposure with cardiovascular disease end points. Because previous reviews have examined the connection between lead and blood pressure in depth ([Table 1](#t1-ehp0115-000472){ref-type="table"}), our systematic review emphasizes other clinical and intermediate cardiovascular outcomes to obtain a broader picture of the impact of lead on cardiovascular disease. Finally, we assessed the causal role of lead on blood pressure and cardiovascular disease by applying the criteria and terminology of the 2004 Surgeon General Report *The Health Consequences of Smoking* \[[@b114-ehp0115-000472]\] to the available information.

Methods
=======

Search strategy and data abstraction
------------------------------------

We aimed to identify all observational studies assessing the association between lead exposure and cardiovascular end points. Using free text and key words ([Appendix A](#app1-ehp0115-000472){ref-type="app"}), we searched PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>), EMBASE (<http://www.embase.com/>), and TOXLINE (<http://toxnet.nlm.nih.gov/>) through August 2006 with no language restrictions. In addition we manually reviewed the reference lists from relevant original research and review articles and documents.

For lead exposure, we included studies that used biomarkers (lead levels in blood, bone, or other specimens), environmental measures (airborne lead levels), or indirect measures (job titles, job exposure matrices, living in lead-contaminated areas). For cardiovascular end points, we included studies that reported clinical cardiovascular end points (cardiovascular disease, coronary heart disease, stroke, or peripheral arterial disease) and intermediate cardiovascular end points (left ventricular mass, heart rate, heart rate variability, or electrocardiographic abnormalities) other than blood pressure levels or hypertension.

We excluded publications containing no original research, studies not carried out in humans, case reports, case series, ecologic studies, studies lacking a cardiovascular outcome, and studies lacking data on lead exposure ([Figure 1](#f1-ehp0115-000472){ref-type="fig"}). For studies with multiple publications on the same population, we selected the publication with the longest follow-up. For studies with equivalent follow-up periods, we selected the study with the largest number of cases or the most recent publication. We excluded autopsy studies measuring lead in arterial tissue and studies based on polycardiography and ballistocardiograpy, techniques no longer in use. For consistency, blood lead levels were converted to micrograms per deciliter.

We adapted the criteria used by [@b61-ehp0115-000472] to assess study quality for studies of clinical end points and the criteria used by [@b5-ehp0115-000472] to assess study quality for studies of intermediate end points (Appendices B and C).

Statistical methods
-------------------

Measures of association (odds ratios, prevalence ratios, standardized mortality ratios, relative risks, relative hazards, comparisons of means, linear regression coefficients, correlation coefficients) and their standard errors were abstracted or derived from published data ([@b38-ehp0115-000472]). For studies reporting measures of association for population subgroups ([@b19-ehp0115-000472]; [@b66-ehp0115-000472]), we pooled the measures of association using an inverse-variance weighted random-effects model ([@b25-ehp0115-000472]).

Because of substantial heterogeneity and methodologic limitations of the original studies, we considered that quantitative pooling was inappropriate. We thus present a qualitative systematic review of the available evidence.

Results
=======

Lead and clinical cardiovascular disease in general populations
---------------------------------------------------------------

Twelve studies met our inclusion criteria ([Table 2](#t2-ehp0115-000472){ref-type="table"}). Lead was measured in blood in all the prospective cohort studies ([@b55-ehp0115-000472]; [@b65-ehp0115-000472]; [@b71-ehp0115-000472]; [@b74-ehp0115-000472]; [@b84-ehp0115-000472]) and in the only cross-sectional study available ([@b75-ehp0115-000472]). Blood lead levels were substantially lower in more recent compared with older studies. Case--control studies assessed lead exposure on the basis of lead levels in blood ([@b50-ehp0115-000472]), plasma ([@b68-ehp0115-000472]), and urine ([@b83-ehp0115-000472]; [@b112-ehp0115-000472]), on a job exposure matrix ([@b39-ehp0115-000472]), and on lead levels in the air of the residential neighborhood of study participants ([@b23-ehp0115-000472]). None of these studies determined lead in bone. Although cohort studies and the cross-sectional study tended to fulfill prespecified quality criteria, case--control studies failed to fulfill some important quality criteria ([Appendix B](#app2-ehp0115-000472){ref-type="app"}).

Lead exposure was positively associated with clinical cardiovascular end points in all studies ([Table 2](#t2-ehp0115-000472){ref-type="table"}). Among prospective studies, the relative risks for coronary heart disease ranged between 1.1 comparing blood lead levels \> 24.8 μg/dL versus \< 12.4 μg/dL in the British Regional Heart Study ([@b84-ehp0115-000472]) and 1.89 comparing blood lead levels ≥ 3.63 μg/dL versus \< 1.93 μg/dL in the National Health and Nutrition Examination Survey (NHANES) III Mortality Follow-up Study ([@b71-ehp0115-000472]). The relative risk for stroke in the NHANES III Mortality Follow-up Study was 2.51. There were no prospective studies on the association of blood lead with peripheral arterial disease. However, the relative risk for peripheral arterial disease comparing blood lead levels ≥ 2.47 μg/dL versus \< 1.03 μg/dL in a cross-sectional analysis of NHANES 1999--2002 was 1.92 ([@b75-ehp0115-000472]).

Lead and cardiovascular mortality in occupational populations
-------------------------------------------------------------

Eighteen studies from the United States ([@b19-ehp0115-000472]; [@b72-ehp0115-000472]; [@b87-ehp0115-000472]; [@b99-ehp0115-000472]; [@b105-ehp0115-000472]; [@b111-ehp0115-000472]), Europe ([@b3-ehp0115-000472]; [@b8-ehp0115-000472]; [@b12-ehp0115-000472]; [@b17-ehp0115-000472], [@b18-ehp0115-000472]; [@b20-ehp0115-000472]; [@b22-ehp0115-000472]; [@b35-ehp0115-000472]; [@b64-ehp0115-000472]; [@b66-ehp0115-000472]; [@b120-ehp0115-000472]), and Australia ([@b70-ehp0115-000472]) met our inclusion criteria ([Table 3](#t3-ehp0115-000472){ref-type="table"}). Battery, ceramic, pigment, refinery, and smelter industries were studied. All studies used job titles to ascertain exposure and death certificates to identify coronary heart disease (12 studies), stroke (15 studies) and overall cardiovascular mortality (9 studies). Most were retrospective cohort studies and used external comparisons to the general population to derive standardized mortality ratios. The exceptions were the study by [@b22-ehp0115-000472], two proportional mortality studies ([@b3-ehp0115-000472]; [@b70-ehp0115-000472]) and two prospective cohort studies ([@b87-ehp0115-000472]; [@b111-ehp0115-000472]). Occupational studies failed to fulfill most prespecified quality criteria ([Appendix B](#app2-ehp0115-000472){ref-type="app"}).

Relative risk estimates across occupational studies varied widely, with positive, inverse, and null associations ([Table 3](#t3-ehp0115-000472){ref-type="table"}). Several studies reported the associations among workers with the heaviest exposure ([@b22-ehp0115-000472]; [@b64-ehp0115-000472]; [@b67-ehp0115-000472]; [@b105-ehp0115-000472]), by year of hire ([@b19-ehp0115-000472]; [@b64-ehp0115-000472]), and incorporating a latency period ([@b64-ehp0115-000472]). In two of the three studies that reported associations by duration of employment, coronary heart disease ([@b105-ehp0115-000472]) and stroke ([@b72-ehp0115-000472]) mortality were higher among workers with the highest number of years of employment.

Lead and intermediate cardiovascular outcomes
---------------------------------------------

Five studies evaluated ventricular wall dimensional and functional parameters ([@b7-ehp0115-000472]; [@b47-ehp0115-000472]; [@b95-ehp0115-000472]; [@b109-ehp0115-000472]; [@b121-ehp0115-000472]) ([Table 4](#t4-ehp0115-000472){ref-type="table"}). Increased blood lead levels were associated with an increased prevalence of left ventricular hypertrophy in U.S. adults ([@b95-ehp0115-000472]) and with a nonstatistically significant increase in left ventricular mass in U.S. battery workers ([@b109-ehp0115-000472]). Similarly, Polish steel workers had higher left ventricular mass and lower ejection fraction compared to administrative workers from the same factory ([@b47-ehp0115-000472]), and lead-exposed Polish workers had impaired diastolic function compared with nonexposed controls ([@b7-ehp0115-000472]). Chinese refinery workers with blood lead levels \> 50 μg/dL had similar interventricular septum and left ventricular wall thickness compared to workers \< 50 μg/dL ([@b121-ehp0115-000472]), although lead levels in the reference category are unknown.

Ten studies measured heart rate variability among lead-exposed workers ([@b4-ehp0115-000472]; [@b10-ehp0115-000472]; [@b29-ehp0115-000472]; [@b34-ehp0115-000472]; [@b45-ehp0115-000472]; [@b77-ehp0115-000472]; [@b76-ehp0115-000472]; [@b78-ehp0115-000472]; [@b82-ehp0115-000472]; [@b110-ehp0115-000472]), and one study measured heart rate variability in Seoul, Korea, public officials not occupationally exposed to lead ([@b46-ehp0115-000472]) ([Table 4](#t4-ehp0115-000472){ref-type="table"}). Most of these studies had limitations in terms of sample size, methods of lead assessment, and lack of adjustment for potential confounders ([Table 4](#t4-ehp0115-000472){ref-type="table"}; [Appendix C](#app3-ehp0115-000472){ref-type="app"}). The conditions for electrocardiographic ascertainment and the heart rate variability indices differed widely across studies, making comparisons difficult. The coefficient of variation of the R-R interval was lower in lead-exposed workers compared with other workers in two of five studies in which the coefficient of variation was measured under normal breathing, and in one of three studies in which it was assessed during deep breathing. Among Seoul public officials ([@b46-ehp0115-000472]), increased lead levels were inversely associated with measures of low frequency, high frequency, and total power spectrum in uni-variate analyses, but adjusted results were not presented because lead exposure was dropped from the stepwise regression models used.

Fifteen studies reported the association of lead with other electrocardiographic parameters ([@b15-ehp0115-000472]; [@b30-ehp0115-000472], [@b32-ehp0115-000472]; [@b48-ehp0115-000472]; [@b51-ehp0115-000472]; [@b53-ehp0115-000472], [@b54-ehp0115-000472]; [@b52-ehp0115-000472]; [@b56-ehp0115-000472]; [@b57-ehp0115-000472]; [@b90-ehp0115-000472]; [@b98-ehp0115-000472]; [@b101-ehp0115-000472], [@b102-ehp0115-000472]; [@b107-ehp0115-000472]) and one study with other vascular abnormalities ([@b2-ehp0115-000472]). All studies, except the Normative Aging Study ([@b15-ehp0115-000472]), were conducted in occupational populations in Europe. These types of outcome, including rhythm disorders, ischemic changes and cycle duration, varied widely across studies, and the findings were inconsistent. The Normative Aging Study measured lead in blood, tibia, and patella and identified associations between tibia lead and intraventricular conduction defects (QRS duration) and increased QT duration in subjects \< 65 years of age ([@b15-ehp0115-000472]).

Finally, heart rate was evaluated using different methods in five studies, four in lead-exposed workers ([@b10-ehp0115-000472]; [@b53-ehp0115-000472]; [@b77-ehp0115-000472]; [@b121-ehp0115-000472]) and one in elderly men from the Netherlands ([@b56-ehp0115-000472]), with inconsistent findings.

Discussion
==========

Lead exposure and hypertension---sufficient evidence to infer a causal relationship
-----------------------------------------------------------------------------------

Chronic lead poisoning was connected to hypertension in the 19th century ([@b63-ehp0115-000472]). With rare exceptions ([@b117-ehp0115-000472]), a major limitation of early reports was the lack of a comparison group ([@b97-ehp0115-000472]). The hypertensive effects of lead have been extensively documented in experimental animals chronically exposed to high lead concentrations and in workers chronically exposed to high lead levels ([@b1-ehp0115-000472]; [@b115-ehp0115-000472]). Generally, the development of hypertension in subjects chronically exposed to high lead levels has been interpreted as a possible consequence of lead nephropathy. At environmental levels of exposure, however, the effect of lead on blood pressure has been controversial. Numerous studies have addressed this question. All reviews have concluded that there is an association between lead and blood pressure, although the strength of this association is modest ([Table 1](#t1-ehp0115-000472){ref-type="table"}). Substantial evidence, however, implies that this relationship is causal.

### Consistency

The association between lead exposure and blood pressure has been found in populations with different geographic, ethnic, and socioeconomic background. While residual confounding by socioeconomic status is a concern, studies in homogenous samples and studies that have adjusted for a variety of socioeconomic indicators have still identified an association between lead exposure and blood pressure ([@b69-ehp0115-000472]; [@b85-ehp0115-000472]).

### Temporality

The association between blood lead and elevated blood pressure has been identified not only in cross-sectional but also in prospective studies that showed that new cases of hypertension and within-person elevations in blood pressure levels over follow-up were related to baseline lead exposure ([@b37-ehp0115-000472]; [@b74-ehp0115-000472]; [@b119-ehp0115-000472]).

### Strength of the association

While the strength of the association between lead and blood pressure is modest, it may have been substantially underestimated because of measurement error in both lead and blood pressure determinations. Most studies used single blood lead measurements to assess lead exposure. When bone lead was used as a bio-marker of long-term exposure ([@b44-ehp0115-000472]), lead in cortical or trabecular bone was positively associated with increased systolic blood pressure or hypertension in all prospective ([@b14-ehp0115-000472]; [@b37-ehp0115-000472]) and cross-sectional studies ([@b36-ehp0115-000472]; [@b43-ehp0115-000472]; [@b49-ehp0115-000472]; [@b59-ehp0115-000472]; [@b69-ehp0115-000472]; [@b89-ehp0115-000472]; [@b93-ehp0115-000472]). Furthermore, even bone lead is subject to error derived from the sampling site and from the technical difficulties of the measurement. In addition, blood pressure measurements were often conducted using nonstandardized protocols, without repeated measures, or in samples including hypertensive subjects.

### Biologic gradient (dose response)

Some studies have demonstrated a progressive dose--response relationship between lead exposure and blood pressure ([@b85-ehp0115-000472]; [@b94-ehp0115-000472]; [@b119-ehp0115-000472]). However, the shape of the dose--response relationship is not completely characterized, particularly at low levels of exposure. It is not known what is the lowest level of lead exposure not associated with blood pressure, although in the available studies there seems to be no evidence of a threshold effect ([@b41-ehp0115-000472]; [@b92-ehp0115-000472]).

### Biologic plausibility and experimental data

Numerous experimental studies in animals have shown irrefutable evidence that chronic exposure to low lead levels results in arterial hypertension that persists long after the cessation of lead exposure ([@b115-ehp0115-000472]). The precise mechanisms explaining a hypertensive effect of low chronic exposure to environmental lead are unknown. An inverse association between estimated glomerular filtration rate and blood lead has been observed at blood lead levels \< 5 μg/dL in general population studies ([@b26-ehp0115-000472]; [@b75-ehp0115-000472]), indicating that lead-induced reductions in renal function could play a major role in hypertension. Other potential mechanisms include enhanced oxidative stress ([@b106-ehp0115-000472]; [@b116-ehp0115-000472]), stimulation of the renin-angiotensin system ([@b11-ehp0115-000472]; [@b88-ehp0115-000472]), and down-regulation of nitric oxide ([@b21-ehp0115-000472]; [@b24-ehp0115-000472]) and soluble guanylate cyclase ([@b27-ehp0115-000472]). These mechanisms could result in increased vascular tone and peripheral vascular resistance ([@b115-ehp0115-000472]).

### Causal inference

We conclude that the evidence is sufficient to infer a causal relationship between lead exposure and high blood pressure. Further research is still needed to determine the precise dose--response relationship, the relative importance of short-term versus chronic lead effects, the relevant mechanisms at environmental levels of exposure, and whether the magnitude of the association is different in children or in other vulnerable population subgroups.

Clinical cardiovascular end points in general populations
---------------------------------------------------------

### Consistency and temporality

Few cohort studies have evaluated the prospective association of lead with clinical cardiovascular outcomes in general population settings. The findings of the NHANES II and NHANES III Mortality Follow-up studies are remarkable. NHANES are periodic, standardized surveys designed to provide representative health data from the U.S. noninstitutionalized population. Despite a marked decline in lead levels in U.S. adults, both surveys showed statistically significant increases in cardiovascular mortality with increasing blood lead ([@b65-ehp0115-000472]; [@b91-ehp0115-000472]). In addition a cross-sectional analysis of NHANES 1999--2002 data identified an association of blood lead with the prevalence of peripheral arterial disease ([@b75-ehp0115-000472]; [@b79-ehp0115-000472]). The British Regional Heart Study ([@b84-ehp0115-000472]) and two other small cohort studies ([@b55-ehp0115-000472]; [@b74-ehp0115-000472]) showed positive but nonstatistically significant associations of coronary heart disease or stroke incidence with higher lead levels. The confidence intervals from these studies were wide but included the point estimates of the NHANES studies. Additional studies are needed to determine the consistency of the evidence in diverse populations.

### Strength of the association and dose response

The associations of blood lead with clinical cardiovascular end points in the NHANES studies were moderately strong, with a clear dose--response gradient. An unresolved issue is the impact of uncontrolled confounding and measurement error on the relative risk estimates in studies of lead and clinical cardiovascular end points. NHANES studies adjusted for race, education, income, and urban versus rural location, which reduces potential confounding by socioeconomic status. Studies with more detailed information on the determinants of lead exposure may contribute to a better understanding of this issue. Similarly, evaluating lead effects using a single blood lead measure may result in measurement error with substantial underestimation of the magnitude of the association. This is particularly problematic when there are marked temporal trends in lead levels, as this source of error adds to within-person variability in blood lead levels to increase regression-dilution bias.

### Biologic plausibility and experimental data

Lead levels of 0.8 ppm ([@b86-ehp0115-000472]) and 0.1 ppm ([@b73-ehp0115-000472]) in drinking water induced atherosclerosis in animal models, and lead levels of 0.5--10 μM induced the proliferation of vascular smooth cells and fibroblasts in *in vitro* models ([@b28-ehp0115-000472]). Lead-related atherosclerosis could be explained by several mechanisms, including increases in blood pressure, impairment of renal function ([@b26-ehp0115-000472]), and induction of oxidative stress ([@b106-ehp0115-000472]; [@b116-ehp0115-000472]), inflammation ([@b40-ehp0115-000472]), and endothelial dysfunction ([@b116-ehp0115-000472]).

### Causal inference

Because of the scarce number of prospective studies and the lack of information on incident nonfatal events, we conclude that the evidence is suggestive but not sufficient to infer a causal relationship with clinical cardiovascular end points. Prospective studies are required to characterize fully the impact of lead on cardiovascular morbidity and mortality. These studies need detailed and repeated assessment of lead exposure and its determinants, standardized assessment of traditional cardiovascular risk factors, and long-term follow-up to identify incident cardiovascular events and trends in subclinical markers of atherosclerosis. Although elevated blood pressure and impaired renal function are proposed mechanisms that mediate the effects of lead on clinical cardiovascular outcomes, other mechanisms are likely to be involved. Future epidemiologic studies should explore in detail the magnitude of the contribution of specific mediators of clinical cardiovascular lead effects.

Cardiovascular mortality in occupational populations
----------------------------------------------------

### Adequacy of the evidence

The validity of occupational studies of lead and cardiovascular mortality is limited by several methodologic problems. A major limitation is the healthy worker effect ([@b6-ehp0115-000472]). The comparison of exposed workers with the general population is particularly inappropriate for cardiovascular mortality because workers are healthier and their lifestyles and cardiovascular risk factors are likely to differ widely from those of the general population ([@b16-ehp0115-000472]). In addition, cardiovascular diseases are associated with prolonged disability and changes in employment status. Even in studies based on comparisons with unexposed workers, the selection of healthier individuals at time of hire or for specific jobs within an industry may have resulted in biased estimates of the association. Correcting the bias introduced by the healthy worker survivor effect is extremely challenging, and stratifying by duration of employment or time since hire is unlikely to completely account for this source of bias ([@b6-ehp0115-000472]; [@b42-ehp0115-000472]).

Additional limitations include the assignment of lead exposure based on job titles and of cardiovascular deaths based on death certificates. Misclassification of exposure and outcome may have resulted in further underestimation of the association of lead and cardiovascular end points. Finally, the lack of determinations of established cardiovascular risk factors and of other occupational exposures may have contributed to uncontrolled confounding.

### Causal inference

As a result of these methodologic limitations, and despite many occupational cohort studies published in the literature ([Table 3](#t3-ehp0115-000472){ref-type="table"}), available information on occupational lead exposure and cardiovascular mortality is inadequate to infer the presence or absence of a causal relationship. Because studies of environmental lead exposure provide evidence of an association between lead and cardiovascular mortality at lower exposures than those experienced by occupationally exposed workers, we expect the impact of lead in exposed workers to be at least as important as in environmentally exposed subjects.

Lead exposure and heart rate variability
----------------------------------------

### Consistency, temporality, and strength of the association

Several studies, mostly cross-sectional, found an association between increased lead exposure and decreased heart rate variability. The diversity in the methods and conditions used for measuring heart rate variability makes it difficult to compare the association of lead exposure and heart rate variability across studies. In addition, the validity and precision of these studies are often limited by small sample sizes, limitations in the assessment of lead exposure, and lack of control for established cardiovascular risk factors and other confounders.

### Biologic plausibility and experimental data

Lead, a well-established neurotoxicant, could affect heart rate variability by interfering in autonomic nervous control of the heart ([@b13-ehp0115-000472]). Heart rate variability measures the fluctuation of the heart rate around the mean heart rate ([@b108-ehp0115-000472]). Because the basis of normal cardiac autonomic functioning is the shift from parasympathetic to sympathetic modulation, decreased heart rate variability is a marker of cardiac autonomic dysfunction. Indeed, decreased heart rate variability in supine position and in response to postural change has been associated with increased incident coronary heart disease and all-cause mortality in large prospective cohort studies in populations free of cardiovascular disease ([@b60-ehp0115-000472]; [@b113-ehp0115-000472]).

### Causal inference

We conclude that the evidence is suggestive of but not sufficient to infer a causal relationship of lead exposure with heart rate variability. Large studies with adequate measures of lead exposure and of heart rate variability are needed to better characterize the association between lead exposure and autonomic cardiac control.

Public health implications
--------------------------

The evidence in this systematic review is sufficient to infer a causal relationship of lead exposure with elevated blood pressure, and it is suggestive of but not sufficient to infer a causal relationship of lead with clinical cardiovascular outcomes and cardiovascular function tests. These associations have been observed at blood lead levels well below 5 μg/dL ([@b71-ehp0115-000472]; [@b80-ehp0115-000472]). Indeed, no lower threshold has been established for any lead-cardiovascular association.

Although future research will contribute to characterize fully the impact of lead exposure on cardiovascular health, these findings have several important public health implications. First, there is an immediate need to lower the current safety standard of the World Health Organization and the U.S. Occupational Safety and Health Administration for blood lead in workers (currently established at 40 μg/dL). Second, a criterion for elevated blood lead levels in adults needs to be established and screened for in preventive services. In fact, the cardiovascular end points described above plus the substantial evidence that chronic lead exposure affects cognitive function ([@b100-ehp0115-000472]) and renal function ([@b26-ehp0115-000472]) at levels \< 5 μg/dL indicate that the U.S. Centers for Disease Control and Prevention criterion for elevated blood levels in children (10 μg/dL) is too high for adults. Third, the hypertensive effects of lead exposure and its impact on cardiovascular mortality need to be included in risk assessment and in economic analyses of lead exposure impact. Finally, regulatory and public health interventions must be developed and implemented to prevent and reduce lead exposure beyond current levels in adults.
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Appendix CCriteria for evaluating the design and data analysis of epidemiologic studies of lead exposure and intermediate cardiovascular end points.[a](#tfn23-ehp0115-000472){ref-type="table-fn"}Ventricular mass and functionHeart rate variabilityOther cardiac abnormalitiesOther vasc.[@b95-ehp0115-000472][@b121-ehp0115-000472][@b109-ehp0115-000472][@b47-ehp0115-000472][@b7-ehp0115-000472][@b76-ehp0115-000472][@b110-ehp0115-000472][@b34-ehp0115-000472][@b77-ehp0115-000472][@b45-ehp0115-000472][@b82-ehp0115-000472][@b10-ehp0115-000472][@b29-ehp0115-000472][@b4-ehp0115-000472][@b78-ehp0115-000472][@b46-ehp0115-000472][@b53-ehp0115-000472][@b54-ehp0115-000472][@b57-ehp0115-000472][@b52-ehp0115-000472][@b51-ehp0115-000472][@b107-ehp0115-000472][@b90-ehp0115-000472][@b56-ehp0115-000472][@b48-ehp0115-000472][@b102-ehp0115-000472]Shcherbak1988[@b101-ehp0115-000472][@b30-ehp0115-000472],[@b31-ehp0115-000472],[@b33-ehp0115-000472][@b32-ehp0115-000472][@b15-ehp0115-000472][@b2-ehp0115-000472]Association estimates based on lead assessed at the individual levelYYYNNNYNNYNNNNNYNNNNNNNYNNNNNNYYAssociation estimates based on blood or bone lead measuresYYYNNNYYNYNNNNNYNNNNNNNYNNNNNNYYCardiovascular tests were based on a standardized protocolYYYYYYYYYYUYYYYYNNYNNNNYYYUYNNYNAuthors indicate that examiners received training to conduct cardiovascular testsYNYNNNNNNNNNNNNNNNNNNNNYYNNNNNYUInclusion and exclusion criteria were similar for all participantsYUYUYYYNYYUYNYUYUUUUUUNYYUYUUUYURecruitment procedures were similar for all participantsYUYUUYYYNYUUNYUYUUUUUUNYYUYUUUYUResponse rate was at least 70%YUNUUUUYUUUUUUUUUUUUUUUYYUUUUUYUExaminer was blinded with respect to the participant exposure statusYUUUUUYUUYUUUUUYUUUUUUUYNUUUUUYUAuthors controlled for relevant confounding factors in addition to age, sexYYYNNNNNNNNNNNNNNNNNNNNYNNNNNNYN[^6][^7]

![Flow diagram of study selection process. Databases: PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>); EMBASE (<http://www.embase.com/>); TOXLINE (<http://toxnet.nlm.nih.gov/>).](ehp0115-000472f1){#f1-ehp0115-000472}

###### 

Reviews of the association between blood lead levels and blood pressure.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                               Type[a](#tfn2-ehp0115-000472){ref-type="table-fn"}   No. of studies included   Year of publication of studies (range)   Language of literature search   Total no. of subjects   Age range of participants (years)   Comparison                                                   Outcome        Pooled estimate \[change in mmHg (95% CI)\]                        Median of estimates \[change in mmHg (range)\]   Conclusions as reported by authors
  ------------------------------------------------ ---------------------------------------------------- ------------------------- ---------------------------------------- ------------------------------- ----------------------- ----------------------------------- ------------------------------------------------------------ -------------- ------------------------------------------------------------------ ------------------------------------------------ --------------------------------------------------------------
  [@b97-ehp0115-000472]                            Review                                               4                         1982--1986                               English, French                 8,406                   24--59                              Per 2-fold ↑[b](#tfn3-ehp0115-000472){ref-type="table-fn"}   SBP            ---                                                                1.9 (0.7 to 2.3)                                 Evidence consistent with causation

  [@b41-ehp0115-000472]                            Review                                               13                        1980--1992                               English                         22,923                  12--80                              ≠ for each study                                             SBP\           ---\                                                               2.0 (−5.9 to 8.0)\                               Evidence strongly supports causal association
                                                                                                                                                                                                                                                                                                                                    DBP\           ---\                                                               1.7 (−1.6 to 4.0)\                               
                                                                                                                                                                                                                                                                                                                                    Hypertension   ---                                                                RR: 1.4 (1.2 to 1.7)                             

  [@b103-ehp0115-000472], [@b104-ehp0115-000472]   SR, MA                                               23                        1980--1993                               English, French, German         33,141                  10--88                              Per 2-fold ↑                                                 SBP\           1.0 (0.4--1.6)\                                                    1.0 (−3.0 to 14.0)\                              MA suggests a weak association
                                                                                                                                                                                                                                                                                                                                    DBP            0.6 (0.2--1.0)                                                     1.0 (−2.0 to 13.0)                               

  [@b96-ehp0115-000472]                            SR, MA                                               15                        1985--1993                               English                         NR\                     18--76                              Per 2-fold ↑[b](#tfn3-ehp0115-000472){ref-type="table-fn"}   SBP            1.25 (0.87--1.63)                                                  1.45 (0.2 to 3.2)                                MA consistent with causal association
                                                                                                                                                                                                           Men only                                                                                                                                                                                                                                                    

  [@b1-ehp0115-000472]                             SR                                                   24                        1980--1996                               No language restriction         NR                      All ages                            ≠ for each study                                             SBP\           ---\                                                               NR\                                              Suggestion of ↑ blood pressure, but evidence is inconclusive
                                                                                                                                                                                                                                                                                                                                    DBP\           ---\                                                               NR\                                              
                                                                                                                                                                                                                                                                                                                                    Hypertension   ---                                                                NR                                               

  [@b81-ehp0115-000472]                            SR, MA                                               31                        1980--2001                               English, French, German         58,518                  10--90                              Per 2-fold ↑                                                 SBP\           1.0 (0.5--1.4)\                                                    1.0 (−5.0 to 14.0)\                              MA suggests a weak association
                                                                                                                                                                                                                                                                                                                                    DBP            0.6 (0.4--0.8)                                                     1.0 (−2.0 to 14.0)                               

  [@b115-ehp0115-000472]                           SR, MA                                               9\                        1990--2003                               English                         27,424\                 14--93                              Per 2-fold ↑                                                 SBP\           0.81 (0.46--1.16)[c](#tfn4-ehp0115-000472){ref-type="table-fn"}\   1.0 (−3.9 to 11)\                                MA suggests an effect of blood lead on SBP
                                                                                                        10                                                                                                 34,740                                                                                                                   DBP            ---                                                                1.0 (−1.3 to 7.3)                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ≠, different; ↑, increase; CI, confidence interval; DBP, diastolic blood pressure; MA, meta-analysis; NHANES, National Health and Nutrition Examination Survey; NR, not reported; RR, relative risk; SBP, systolic blood pressure; SR, systematic review; U.S. DHHS, U.S. Department of Health and Human Services; U.S. EPA, U.S. Environmental Protection Agency.

Systematic review: a search strategy and criteria for manuscript selection are specified. Meta-analysis: a pooled analysis using meta-analysis techniques are presented.

In the study by [@b97-ehp0115-000472], we divided by 3 the change per 15 μg/dL (equivalent to comparing 10 μg/dL vs. 5 μg/dL). The study by [@b96-ehp0115-000472] reports the change in mmHg comparing 10 μg/dL vs. 5 μg/dL.

Pooled estimate using an inverse variance weighted random-effects model ([@b25-ehp0115-000472]) of two pooled estimates for linear and log-linear estimates, respectively.

###### 

Epidemiologic studies of lead exposure and clinical cardiovascular disease in general populations.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                          Country       Population                           Men (%)   Age range (years)   Lead assessment   Range of lead levels             End point ascertainment                                                                      Outcome          No. of cases/noncases   Measure of[b](#tfn7-ehp0115-000472){ref-type="table-fn"} association   Comparison                     Adjusted for[c](#tfn8-ehp0115-000472){ref-type="table-fn"}
  ------------------------------------------- ------------- ------------------------------------ --------- ------------------- ----------------- -------------------------------- -------------------------------------------------------------------------------------------- ---------------- ----------------------- ---------------------------------------------------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------
  Prospective cohort studies                                                                                                                                                                                                                                                                                                                                                                                                  

   [@b84-ehp0115-000472]                      U.K.          British Regional Heart Study         100       40--49              Blood (AAS)       \< 6.2 to \> 35.2 μg/dL          Death certificate or chest pain, enzyme, ECG[a](#tfn6-ehp0115-000472){ref-type="table-fn"}   CHD, F + NF      316/7,063               OR 1.1 (0.4--1.8)                                                      \> 24.8 vs. \< 12.4 μg/dL      Age, smoking, location

                                                                                                                                                                                  Death certificate, medical record                                                            Stroke, F + NF   66/7,313                Mean 16.7 μg/dL\                                                       Cases vs. noncases             Age, smoking, location
                                                                                                                                                                                                                                                                                                                        Mean 15.3 μg/dL                                                                                       

   [@b55-ehp0115-000472]                      Netherlands   Elderly men in Zutphen               100       57--76              Blood (AAS)       \< 10.8 (10th p)\                Death certificate or chest pain, enzyme, ECG[a](#tfn6-ehp0115-000472){ref-type="table-fn"}   CHD, F + NF      26/115                  HR 1.34 (0.46--3.94)                                                   \> 23.8 vs. \< 13.0 μg/dL      Age, smoking, BMI, BP, cholesterol
                                                                                                                                                 \> 28.0 (90th p) μg/dL                                                                                                                                                                                                                                                       

   [@b74-ehp0115-000472]                      Denmark       Survey repondents 4 municipalities   48        40                  Blood (AAS)       2 to 60 μg/dL                    Death certificate, hospital admissions                                                       CHD, F + NF\     40/1,005\               HR 1.58 (0.85--2.95)\                                                  Per log unit change            Sex, smoking, alcohol, BP, cholesterol, exercise
                                                                                                                                                                                                                                                                               CVD, F + NF      54/991                  HR 1.10 (0.63--1.93)                                                                                  

   [@b65-ehp0115-000472]                      U.S.          NHANES II                            47        30--74              Blood (AAS)       \< 10 to 29 μg/dL                Death certificate                                                                            CVD, F           424/3,766               HR 1.39 (1.01--1.91)                                                   20--29 vs. \< 10 μg/dL         Age, sex, race, educ., income, smoking, BMI, exercise, location

   [@b71-ehp0115-000472]                      U.S.          NHANES III                           47        ≥ 17                Blood (AAS)       \< 1 to 10 μg/dL                 Death certificate                                                                            CVD, F\          766/13,198\             HR 1.55 (1.08--2.24)\                                                  \< 1.93 vs. ≥ 3.63 μg/dL       Age, sex, race, educ., income, smoking, alcohol, BMI, exercise, cholesterol, CRP, urban residence, menopause, hypertension, kidney function
                                                                                                                                                                                                                                                                               CHD, F\          367/13,597\             HR 1.89 (1.04--3.43)\                                                                                 
                                                                                                                                                                                                                                                                               Stroke, F        141/13,823              HR 2.51 (1.20--5.26)                                                                                  

  Case--control and cross-sectional studies                                                                                                                                                                                                                                                                                                                                                                                   

   [@b83-ehp0115-000472]                      Taiwan        Clinic-based                         69        NR                  Urine (DPASV)     7.9 to 138.4 μg/L                NR                                                                                           BFD prev.        16/16                   30.8 (30.1) μg/L\                                                      Cases vs. noncases             Age, sex
                                                                                                                                                                                                                                                                                                                        17.4 (5.4) μg/L                                                                                       

   [@b68-ehp0115-000472]                      Sweden        Clinic-based                         53        Mean 46             Plasma (TRXFS)    Mean 3.3 ng/g plasma             Angiograms                                                                                   PAD prev.        65/65                   3.3 (0.4) ng/g plasma\                                                 Cases vs. noncases             Age, sex
                                                                                                                                                                                                                                                                                                                        3.2 (0.3) ng/g plasma                                                                                 

   [@b39-ehp0115-000472]                      Sweden        SHEEP Study                          68        45--70              JEM               NM                               Chest pain, ECG enzyme[a](#tfn6-ehp0115-000472){ref-type="table-fn"}                         AMI inc., NF     1,335/1,658             OR 1.03 (0.64--1.65)                                                   ≥ 0.04 mg/m^3^ vs. unexp.      Age, sex, smoking, alcohol, BP, BMI, exercise, location

   [@b23-ehp0115-000472]                      Lithuania     Clinic-based                         100       25--64              Airborne          NM                               Medical records                                                                              AMI              579/1,777               OR 1.12 (0.76--1.40)                                                   \> 0.225 vs. ≤ 0.225 μg/m^3^   Age, sex, smoking, BP

   [@b112-ehp0115-000472]                     Taiwan        Clinic-based                         57        NR                  Urine (AAS)       5.3 to 123.6 μg/L                NR                                                                                           BFD prev.        68/68                   33.7 (24.3) μg/L\                                                      Cases vs. noncases             Age, sex
                                                                                                                                                                                                                                                                                                                        22.2 (11.8) μg/L                                                                                      

   [@b50-ehp0115-000472]                      Poland        Clinic-based                         53        Mean 62             Blood (AAS)       Mean 3.9 μg/dL                   Coronariography, treadmill exercise text                                                     Effort angina    33/18                   3.9 (1.4) μg/dL\                                                       Cases vs. noncases             Crude
                                                                                                                                                                                                                                                                                                                        3.7 (1.2) μg/dL                                                                                       

   [@b75-ehp0115-000472]                      U.S.          NHANES 1999--2002                    47        ≥ 40                Blood (AAS)       \< 0.3 to \> 10 (98th p) μg/dL   Ankle-brachial BP index                                                                      PAD prev.        NR                      OR 1.92 (1.02--3.61)                                                   ≥ 2.47 vs. \< 1.06 μg/dL       Age, sex, race, educ., insurance, smoking, alcohol, BMI, diabetes
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AAS, atomic absorption spectrometry; AMI, acute myocardial infarction; BFD, black foot disease, a form of peripheral arterial disease endemic in the arseniasis areas of southwestern Taiwan; BMI, body mass index; BP, blood pressure levels or hypertension; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; DPASV, differential pulse anodic stripping voltammetry; ECG, electrocardiogram; educ., education; F, fatal; F+NF, fatal and nonfatal; HR, hazard ratio; inc., incidence; JEM, job exposure matrix; NF, nonfatal; NHANES, National Health and Nutrition Examination Survey; NM, not measured; NR, not reported; OR, odds ratio; PAD, peripheral arterial disease; p, percentile; prev, prevalence; SHEEP, Stockholm Heart Epidemiology Study; TRXFS, total-reflection X-ray fluorescence spectrometry; unexp., unexposed.

Standard World Health Organization criteria for myocardial infarction.

For studies that categorized lead exposure, we report the HR or OR (with 95% CI in parentheses) comparing the highest with the lowest lead category. Otherwise, we present the mean (SD) lead levels for cases and noncases.

Blood pressure--unadjusted relative risk is as follows: *a*) [@b71-ehp0115-000472]: cardiovascular mortality 1.64, coronary heart disease mortality 2.01, stroke mortality 2.61; *b*) [@b39-ehp0115-000472]: acute myocardial infarction 1.17.

###### 

Epidemiologic studies of cardiovascular mortality in occupational populations exposed to lead.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                              Country     Population                                        Men (%)   Age range (years)              Outcome                                              Follow-up (years)   No. of deaths[a](#tfn11-ehp0115-000472){ref-type="table-fn"}   RR (95% CI)[b](#tfn12-ehp0115-000472){ref-type="table-fn"}         Comparison                                                          Adjusted for                                                                                       Corrected for healthy worker effect
  ----------------------------------------------- ----------- ------------------------------------------------- --------- ------------------------------ ---------------------------------------------------- ------------------- -------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Prospective cohort studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

   [@b87-ehp0115-000472]                          U.S.        Tetraethyl lead production workers                100       20--58                         CVD                                                  20                  57 *n* = 1,252                                                 0.64 (0.54--0.75)                                                  Production vs. maintenance workers                                  Crude                                                                                              No

   [@b111-ehp0115-000472]                         U.S.        Orchard workers (lead arsenate)                   66        8 to ≥ 55                      CHD\                                                 45                  NR\                                                            1.27 (0.72--2.23)\                                                 Workers vs. general population                                      Age, sex                                                                                           No
                                                                                                                                                         Stroke                                                                   NR *n* = 1,097                                                 0.82 (0.31--2.12)                                                                                                                                                                                                                         

  Retrospective cohort studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

   [@b22-ehp0115-000472]                          U.K.        Lead pensioners and workers                       100       ≥ 65\                          Stroke                                               35                  51                                                             2.73 (1.31--5.71)[c](#tfn13-ehp0115-000472){ref-type="table-fn"}   Assembly, plumbers, plate cutting, etc. vs. office, chemist, etc.   Age, period                                                                                        No
                                                                                                                          Mean 55                                                                                                                                                                                                                                                                                                                                                                                                          

   [@b66-ehp0115-000472], [@b67-ehp0115-000472]   U.K.        Lead battery and smelter pensioners and workers   99        \< 65 to ≥ 65 at death         CHD\                                                 10\                 99\                                                            1.00 (0.82--1.22)\                                                 Workers vs. general population\                                     Age                                                                                                No
                                                                                                                                                         Stroke                                               51                  103                                                            1.31 (0.66--1.91)                                                  High exposed vs. no exposed                                                                                                                                            

   [@b99-ehp0115-000472]                          U.S.        Pigment plant workers                             100       Mean 27.8                      CVD[d](#tfn14-ehp0115-000472){ref-type="table-fn"}   31                  139                                                            0.62 (0.52--0.73)                                                  Workers vs. general population                                                                                                                                         

   [@b20-ehp0115-000472]                          U.K.        Pigment plant workers\                            100\      18--59\                        Stroke\                                              30\                 31\                                                            0.94 (0.66--1.33)\                                                 Workers vs. general population\                                     Age, period\                                                                                       No\
                                                              Pigment plant workers + lead poisoning            100       18--59                         Stroke                                               30                  9                                                              4.10 (2.12--7.86)                                                  Workers vs. general population                                      Age, period                                                                                        No

   [@b19-ehp0115-000472]                          U.S.        Lead battery and producing workers                100       \< 25--74                      CVD\                                                 24                  984\                                                           0.97 (0.99--1.06)\                                                 Workers vs. general population                                      Age (\~ findings by year of hire and employment duration)                                          Partially[e](#tfn15-ehp0115-000472){ref-type="table-fn"}
                                                                                                                                                         CHD\                                                                     715\                                                           0.85 (0.69--1.05)\                                                                                                                                                                                                                        
                                                                                                                                                         Stroke                                                                   172                                                            1.06 (0.76--1.48)                                                                                                                                                                                                                         

   [@b8-ehp0115-000472]                           Italy       Lead miners                                       100       NR                             CVD                                                  36                  82                                                             0.95 (0.76--1.10)                                                  Workers vs. general population                                      Age                                                                                                No

   [@b72-ehp0115-000472]                          U.S.        Newspaper print workers                           100       19--83                         CHD\                                                 23                  186\                                                           0.63 (0.54--0.73)\                                                 Workers vs. general population                                      Age (for stroke, analysis by employment duration[f](#tfn16-ehp0115-000472){ref-type="table-fn"})   Partially
                                                                                                                                                         Stroke                                                                   43                                                             1.35 (0.98--1.82)                                                                                                                                                                                                                         

   [@b105-ehp0115-000472]                         U.S.        Smelter workers                                   100       NR                             CHD\                                                 39\                 320\                                                           0.94 (0.84--1.05)\                                                 Workers vs. general population\                                     Age, period (+ analyses by employment duration[g](#tfn17-ehp0115-000472){ref-type="table-fn"})\    Partially
                                                                                                                                                         Stroke\                                              39                  74\                                                            1.05 (0.82--1.32)\                                                 High exposed vs. general population                                 Age, period                                                                                        
                                                                                                                                                         CHD\                                                                     239\                                                           0.99 (0.87--1.12)\                                                                                                                                                                                                                        
                                                                                                                                                         Stroke                                                                   53                                                             1.05 (0.79--1.37)                                                                                                                                                                                                                         

   [@b18-ehp0115-000472]                          Italy       Lead miners                                       100       Mean 27.7                      CVD                                                  28                  258                                                            0.63 (0.56--0.72)                                                  Workers vs. general population                                      Age, period (\~ findings for surface and underground workers)                                      No

   [@b35-ehp0115-000472]                          Sweden      Smelter workers                                   100       NR                             CHD\                                                 20                  34\                                                            1.72 (1.20--2.42)\                                                 Workers vs. general population                                      Age, period (\~ findings by year of hire)                                                          No
                                                                                                                                                         Stroke                                                                   0                                                              0 (0.00--1.23)                                                                                                                                                                                                                            

   [@b64-ehp0115-000472]                          Sweden      Smelter workers                                   100       15 to ≥ 75 at death            CVD\                                                 32                  234\                                                           0.90 (0.80--1.00)\                                                 Workers vs. general population                                      Age, period (\~ findings for highest exposure group and adding a latency period)                   No
                                                                                                                                                         CHD\                                                                     152\                                                           0.80 (0.70--1.00)\                                                                                                                                                                                                                        
                                                                                                                                                         Stroke                                                                   36                                                             0.80 (0.60--1.20)                                                                                                                                                                                                                         

   [@b17-ehp0115-000472]                          Italy       Smelter workers                                   100       Mean 30.4                      CVD\                                                 48                  251\                                                           0.70 (0.62--0.80)\                                                 Workers vs. general population                                      Age, period                                                                                        No
                                                                                                                                                         CHD\                                                                     49\                                                            0.34 (0.25--0.45)\                                                                                                                                                                                                                        
                                                                                                                                                         Stroke                                                                   105                                                            0.95 (0.77--1.15)                                                                                                                                                                                                                         

   [@b120-ehp0115-000472]                         Poland      Workers compensated for lead poisoning            100       \< 29 to ≥ 50 at 1st episode   CVD\                                                 22                  231\                                                           0.91 (0.80--1.04)\                                                 Workers vs. general population                                      Age (\~ findings by number of lead poisoning episodes)                                             No
                                                                                                                                                         CHD\                                                                     98\                                                            0.96 (0.78--1.17)\                                                                                                                                                                                                                        
                                                                                                                                                         Stroke                                                                   33                                                             1.03 (0.71--1.45)                                                                                                                                                                                                                         

   [@b12-ehp0115-000472]                          Italy       Smelter workers                                   100       NR                             CVD                                                  29                  28                                                             0.80 (0.56--1.16)                                                  Workers vs. general population                                      Age                                                                                                No

  Proportional mortality study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

   [@b3-ehp0115-000472]                           Bulgaria    Smelter workers                                   100       Mean at death 61               CHD\                                                 10                  26\                                                            5.60 (1.68--18.6)\                                                 Workers vs. general population                                      Age                                                                                                No
                                                                                                                                                         Stroke                                                                   47                                                             0.17 (0.08--0.36)                                                                                                                                                                                                                         

   [@b70-ehp0115-000472]                          Australia   Smelter workers                                   100       30 to \> 60 at death           CHD\                                                 40                  231\                                                           0.95 (0.67--1.35)\                                                 Exposed workers vs. staff workers                                   Age                                                                                                No
                                                                                                                                                         Stroke                                                                   53                                                             1.45 (0.76--2.76)                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular; RR, relative risk; SMR, standard mortality ratio.

In all studies, lead exposure was determined through job titles, and mortality outcomes were assigned through information in death certificates.

Sample size not available in most studies.

Relative risk estimates came from SMRs except [@b87-ehp0115-000472] (RR), [@b111-ehp0115-000472] (HR), [@b3-ehp0115-000472] (proportional mortality rate), and [@b70-ehp0115-000472] (proportional mortality rate).

The within-cohort relative risk was estimated by comparing standardized mortality ratios in the highest versus the lowest category of exposure.

A total of 15% of subjects with unknown cause of death in death certificate.

Partial adjustment indicates that authors conducted additional analyses by employment duration.

For [@b72-ehp0115-000472], SMRs (95%CI) for stroke by number of years of employment are \< 10 years, 2.52 (0.06--13,93); 10--19 years, 0.32 (0.01--1.74); 20--29 years, 0.65 (0.18--1.68); ≥ 30 years, 1.68 (1.18--2.31).

For [@b105-ehp0115-000472], SMRs by numbers of years of employment are as follows: *a*) CHD: 1--5 years, 1.02; 5--20 years, 0.92; ≥ 20 years, 0.86. *b*) Stroke: 1--5 years, 0.83; 5--20 years, 1.01; ≥ 20 years, 1.41.

###### 

Epidemiologic studies of lead exposure and intermediate cardiovascular end points.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year                                                   Country       Population                                 Sample size (no.)   Men (%)   Age range (years)   Lead assessment      Range levels (μg/dL)         Comparison                                                   End point ascertainment                        Main findings
  -------------------------------------------------------------------- ------------- ------------------------------------------ ------------------- --------- ------------------- -------------------- ---------------------------- ------------------------------------------------------------ ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies of ventricular mass and function                                                                                                                                                                                                                                                                                                      

   [@b95-ehp0115-000472]                                               U.S.          NHANES II                                  \< 9,932            \~ 50     25--74              Blood                NR                           Per 1 μg/dL                                                  ECG (Minnesota code)                           ↑ prevalence left ventricular hypertrophy\
                                                                                                                                                                                                                                                                                                                                                OR adjusted for age, sex, race = 1.33 (95% CI, 1.09--1.61)

   [@b121-ehp0115-000472]                                              China         Refinery workers                           41                  81        24--45              Blood                Mean\                        \> 50 vs. \< 50 μg/dL                                        US (dimensional and functional parameters)     \~ end-diastolic, systolic internal dimension, wall thickness\
                                                                                                                                                                                                       42.5                                                                                                                                     \~ ejection fraction (%), cardiac output (mL/sec), index (mL/sec × m^2^\
                                                                                                                                                                                                                                                                                                                                                \~ heart rate

  [@b109-ehp0115-000472]                                               U.S.          Battery workers                            108                 51        36--73              Blood                12--50                       34--50 vs. 12--25 μg/dL                                      US and ECG                                     ↑ left ventricular mass (g/m^2^) but NS (*p* = 0.20)

   [@b47-ehp0115-000472]                                               Poland        Steel workers                              143                 NR        Mean\               Blood                Mean\                        Administrative workers                                       US (dimensional and functional parameters)     ↑ left ventricular mass (g and g/m^2^)\
                                                                                                                                                              44                                       23.4                                                                                                                                     ↑ left, \~ right end-diastolic internal dimensions\
                                                                                                                                                                                                                                                                                                                                                \~ wall thickness (interventricular septum, posterior wall, others)\
                                                                                                                                                                                                                                                                                                                                                ↓ ejection fraction (%)

   [@b7-ehp0115-000472]                                                Poland        Lead workers                               104                 100       32--56              Blood                19.3--79.8                   Lead exposed vs. control                                     Echo-doppler                                   ↓ early mitral inflow peak velocity, ↑ late mitral inflow peak velocity\
                                                                                                                                                                                                                                                                                                                                                ↓ time velocity integral of early vs. late diastolic inflow\
                                                                                                                                                                                                                                                                                                                                                \~ time velocity integral of early vs. total diastolic inflow\
                                                                                                                                                                                                                                                                                                                                                ↑ time velocity integral of late vs. total diastolic inflow\
                                                                                                                                                                                                                                                                                                                                                \~ Isovolumetric relaxation time of left ventricle

  Studies of heart rate variability                                                                                                                                                                                                                                                                                                             

   [@b76-ehp0115-000472]                                               Japan         Gun workers                                32                  100       23--58              Job title            \< 16--60                    Other workers no lead exp.                                   ECG: 100 R-R intervals, normal breath          ↓ CV of R-R interval; \~ CV of LF component, ↓ CV of HF component

   [@b110-ehp0115-000472]                                              Japan         Battery, refinery workers                  172                 100       18--57              Blood                5--76                        Correlation, \> 50 vs. \< 20 μg/dL                           ECG: 1 min, normal, deep breath                \~, ↓ mean; \~, ↓ SD; and \~, ↓ CV of R-R interval\
                                                                                                                                                                                                                                                                                                                                                \~, ↓ maximal variation ratio (min/max R-R interval)\
                                                                                                                                                                                                                                                                                                                                                \~, ↓ maximal variation rate (\[min/max R-R interval\]/mean)

   [@b34-ehp0115-000472]                                               Belgium       Battery workers                            183                 100       22--55              Blood                4.4--75                      Other workers (finishing, maintenance, etc.)                 ECG: normal, deep breath                       \~ CV of R-R interval, \~ CV of mean square of successive differences, and \~ CV of mean ratio of shortest to longest R-R

   [@b77-ehp0115-000472]                                               Japan         Glass workers                              51                  0         21--35              Job title            NR                           Textile workers                                              ECG: 100 R-R intervals, normal breath          \~ heart rate\
                                                                                                                                                                                                                                                                                                                                                ↓ CV of R-R interval, ↓ CV of LF and ↓ HF components\
                                                                                                                                                                                                                                                                                                                                                ↓ LF/HF ratio

   [@b45-ehp0115-000472]                                               Japan         Ceramic painters                           128                 45        29--75              Blood                2.1--69.5                    \> 30 vs. \< 10 μg/dL                                        ECG: 100 R-R intervals, normal, deep breath\   \~ CV of R-R interval\
                                                                                                                                                                                                                                                                                                 Doppler: finger blood flow                     ↓ flow between supine and standing/supine\
                                                                                                                                                                                                                                                                                                                                                \~ flow drop velocity (supine flow/time to the nadir after standing)

   [@b82-ehp0115-000472]                                               China         Lead-exposed workers                       302                 NR        20--59              Job title            NM                           Healthy controls                                             ECG: deep breath, valsalva, stand up           \~ R-R interval

   [@b10-ehp0115-000472]                                               Germany       Lead, iron, steel workers                  136                 100       Mean\               Blood                Mean lead workers\           Iron steel workers                                           ECG: 90 min, 10-step battery test              ↓ heart rate at rest\
                                                                                                                                                              43                                       31.2                                                                                                                                     ↑ sinus arrhythmia at rest\
                                                                                                                                                                                                                                                                                                                                                Lack of recovery of LF and HF after test

   [@b29-ehp0115-000472]                                               Poland        Foundry workers                            35                  100       Mean\               Blood                \< 3.6 to \> 41.0            Healthy controls                                             ECG: 24 hr, long- and short-term               \~ mean R-R, SDNN, SDNN index, SDANN, rMSSD, pNN50\
                                                                                                                                                              42                                                                                                                                                                                Short-term only: \~ TP, VLF, LF, HF, LF/HF, HF night / HF day

   [@b4-ehp0115-000472]                                                Poland        Copper smelter workers                     86                  100       Mean\               Blood                Mean lead workers,br\>46.8   Healthy controls matched on age, sex, smoking, lipids, BMI   ECG: 24 hr                                     \~ heart rate\
                                                                                                                                                              43                                                                                                                                                                                Long-term: ↓ pNN50, \~ mean R-R, SDNN, SDNN index, SDANN, rMSSD\
                                                                                                                                                                                                                                                                                                                                                Short-term: all parameters ↓ included LF and HF, except mean R-R and LF:HF

   [@b78-ehp0115-000472]                                               Italy         Battery workers                            78                  96        Mean\               Blood                \< 3.5 to \> 31.6            Other workers                                                ECG: battery tests                             ↓ R-R interval ratios for lying-standing, lying-standing-lying, deep breaths, and valsalva
                                                                                                                                                              38                                                                                                                                                                                

   [@b46-ehp0115-000472]                                               Korea         Public officials and family                331                 55        Mean\               Blood                \< 1.39 to \> 3.45           Per natural-log unit                                         ECG: 3 min, seated position                    ↓ LF, HF, and total power spectrum
                                                                                                                                                              38                                                                                                                                                                                

  Studies of other cardiac function abnormalities                                                                                                                                                                                                                                                                                               

   [@b53-ehp0115-000472]                                               Poland        Lead-poisoned workers                      140                 100       18--45              Job title symptoms   NM                           Healthy controls                                             ECG                                            ↓ heart rate, ↓ P-Q interval\
                                                                                                                                                                                                                                                                                                                                                ↑ heart muscle lesions and vegetative disorders

   [@b54-ehp0115-000472]                                               Poland        Lead-poisoned workers                      76                  100       46--65              Job title symptoms   NM                           Healthy controls                                             ECG                                            ↑ heart muscle lesions and vegetative disorders

   [@b57-ehp0115-000472]                                               Poland        Lead-poisoned workers                      591                 78        20--68              Job title symptoms   NM                           Other workers                                                ECG                                            ↑ prevalence of ischemic changes: 32% vs. 13%

   [@b52-ehp0115-000472]                                               Poland        Lead-poisoned workers                      100                 100       20--45              Job title symptoms   NM                           Healthy controls                                             ECG                                            ↑ heart muscle lesions and vegetative disorders

   [@b51-ehp0115-000472]                                               Poland        Lead-poisoned workers                      216                 100       18--65              Job title symptoms   NM                           Healthy controls                                             ECG                                            ↑ heart muscle lesions and vegetative disorders

   [@b107-ehp0115-000472]                                              Yugoslavia    Lead-poisoned workers                      1,000               100       NR                  Job title symptoms   NM                           Healthy controls                                             ECG questionnaire                              ↑ electrocardiographic abnormalities (including ↑ S-T segment)\
                                                                                                                                                                                                                                                                                                                                                ↑ self-reported coronary heart disease and intermittent claudication

   [@b90-ehp0115-000472]                                               Croatia       Residents near to and far from a smelter   502                 50        26--70              Area of residency    NM                           Residents far from smelter                                   ECG                                            \~ electrocardiographic abnormalities

   [@b56-ehp0115-000472]                                               Netherlands   Elderly men in Zutphen                     152                 100       57--76              Blood                \< 10.8\                     Correlation                                                  ECG                                            \~ resting heart rate
                                                                                                                                                                                                       \> 28.0                                                                                                                                  

   [@b48-ehp0115-000472]                                               Denmark       Lead smelter workers                       190                 89        30--60              Job title            Mean 31                      Healthy controls residents in Glostrup                       ECG (Minnesota code)                           ↑ prevalence of ischemic changes: 20% vs. 6%

   [@b102-ehp0115-000472]                                              Poland        Lead workers                               250                 100       Mean\               Job title            NM                           Other workers                                                ECG (Minnesota code)                           ↑ prevalence of ischemic changes: 10.0% vs. 5.3%\
                                                                                                                                                              41                                                                                                                                                                                ↑ prevalence of rhythm disorders: 14% vs. 2.7%

   [@b98-ehp0115-000472]                                               Russia        Lead workers                               320                 100       20--59              Job title            NM                           Other workers                                                ECG                                            ↑ prevalence of ischemic changes: 11.6% vs. 6.7%

   [@b101-ehp0115-000472]                                              Poland        Lead workers                               711                 100       20--60              Job title            NM                           Other workers                                                ECG (Minnesota code)                           ↑ prevalence systolic murmur and rhythm disorders\
                                                                                                                                                                                                                                                                                                                                                ↑ prevalence ventricular repolarization\
                                                                                                                                                                                                                                                                                                                                                \~ prevalence of ischemic changes

   [@b30-ehp0115-000472],[@b31-ehp0115-000472],[@b33-ehp0115-000472]   Russia        Lead workers                               500                 78        20--60              Job title            Mean\                        Other workers                                                Integral rehography\                           Changes of intracardial and peripheral hemodynamics\
                                                                                                                                                                                                       67                                                                                        ECG                                            Disorders of myocardial bioelectric activity and contractility\
                                                                                                                                                                                                                                                                                                                                                ↑ P wave and QT, QRS interval; \~ P--Q interval

   [@b32-ehp0115-000472]                                               Russia        Lead workers                               68                  100       NR                  Job title            NM                           Other workers                                                Exercise stress test                           ↑ prevalence of ischemic changes (↑ S-T segment \> 1 mm 15.9 vs. 4.2%)

   [@b15-ehp0115-000472]                                               U.S.          NormativeAging Study                       775                 100       48--93              Blood\               Mean 5.79\                   Per 10 unit ↑                                                ECG                                            Subjects \< 65 years: ↑ QT, ↑ QRS interval for tibia and patella, \~ for blood\
                                                                                                                                                                                  Tibia\               Mean 22 μg/g\                                                                                                                            Subjects ≥ 65 years: \~ QT, \~ QRS interval for all biomarkers\
                                                                                                                                                                                  Patella              Mean 31 μg/g                                                                                                                             \~ conduction defects and arrhythmia for all biomarkers, indices and age groups, except ↑ intraventricular conduction defect for tibia lead in \< 65 years

  Studies of other vascular function abnormalities                                                                                                                                                                                                                                                                                              

   [@b2-ehp0115-000472]                                                Japan         Refinery workers                           48                  100       18--69              Job title            Mean 43.2                    Correlation                                                  Acceleration plethysmography                   ↓ amplitude ratio of the second/first systolic wave (age adjusted)\
                                                                                                                                                                                                                                                                                                                                                \~ amplitude ratio of the third/first and third/first waves (age adjusted)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ↑, ↓ -- indicate increase or decrease (statistically significant at *p* \< 0.05, unless otherwise specified). BMI, body mass index; CI, confidence interval; CV, coefficient of variation; DB, deep breathe; ECG, electrocardiogram; exp., exposed; HF, high frequency; HRV, heart rate variability; LF, low frequency; NM, not measured; NR, not reported; NS, not significant; OR, odds ratio; pNN50, proportion of interval differences of successive normal-to-normal intervals \> 50 msec; RMSSD, square root of the mean-squared differences of successive NN intervals; SD, standard deviation; SDANN, SD of the average normal-to-normal interval. SDNN, SD of the normal-to-normal interval; TP, total power; US ultrasound; V, ventricular; VLF, very low frequency.
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